Positron Corporation (POSC)

[chmcnfunds]

Positron Corp (POSC) Upgraded by Zacks to NEUTRAL

September 9, 2011 at 12:36 pm by SR Staff

Zacks Investment Research upgraded shares of Positron Corp (POSC) from N/A to NEUTRAL on September 09, 2011, with a target price of $0.04.

Positron's fortunes could improve as a result of a favorable shift in industry dynamics coupled with major new developments at the company including significant product introductions, a co-development deal with medical device heavyweight Covidien, the acquisition of a radiopharmaceutical manufacturing facility and a partnership to build a high energy cyclotron. Sales of POSC's PET scanner have been significantly below management's expectations, although we forecast this to pick up in 2012. Fuel for long-term growth is expected to come from radiopharmaceuticals development, an area POSC has just begun to enter. Risks include a high cash burn rate, the need to continue to find additional financing, extremely thin gross margins, significant possibility of further shareholder dilution, slow PET placement rate and uncertainty about the ultimate success of POSC's radiopharmaceutical manufacturing aspirations. We value the company at $0.04/share and are initiating coverage of POSC with a Neutral rating.
_________________________________________________________
http://www.stockrants.com/2011/09/09/positron-corp-posc-upgraded-by-zacks-to-neutral.html

Glad to see they are covering Positron.

POSC